Stéphane De Wit, MD

CHU St-Pierre, Belgium

Disclosure(s): AstraZeneca: Honoraria, Speaker fees; Gilead: Honoraria, Speaker fees, Advisory Board; GSK: Honoraria, Speaker fees; Janssen: Honoraria, Speaker fees; Merck: Honoraria, Speaker fees, Advisory Board; Pfizer: Advisory Board; Sanofi: Honoraria, Speaker fees; ViiV Healthcare/GSK: Advisory Board

Poster(s):

• (P-1960) Safety and Pharmacokinetics of Long-acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent after Repeat Dosing: Results from the PROVENT Substudy
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT